Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002548 · ClinicalTrials.gov registry record · Phase 3
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 899
- Enrollment target
NCT00002548 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 899 participants.
The verdict
NCT00002548, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 899 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of melphalan, total-body irradiation, and peripheral stem cell transplantation with that of combination chemotherapy in treating patients who have previously untreated multiple myeloma.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG carmustine
- DRUG doxorubicin hydrochloride
- BIOLOGICAL recombinant interferon alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 899 participants |
| Start Date | 1994-01 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002548
The ClinicalTrials.gov registry entry for NCT00002548 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 899 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002548 about?
NCT00002548 is a clinical study titled "SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to gi...
What is the current status of trial NCT00002548?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 899 participants. The study started on 1994-01. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00002548?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), carmustine (DRUG), doxorubicin hydrochloride (DRUG), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002548?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.